Terns Pharmaceuticals, Inc., a biopharmaceutical company with a market capitalization of $397 million, disclosed the departure of their Chief Financial Officer (CFO), Mark Vignola, Ph.D., effective ...

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

Q4 2024 Management View CEO Soren Tulstrup highlighted full-year 2024 revenue of SEK 171.3 million, marking a 28% year-over-year increase, with IDEFIRIX product sales contributing SEK 140.1 million ...

The successful financings come amid a more than two-year stretch when the sector has struggled to attract fresh capital with ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

BioPharma announced that its licensee Celly Nutrition Corporation, the company behind unbuzzd announced that it has engaged a leading New York ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at ...

Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term.

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

BioSpace Senior Editor Annalee Armstrong headed to the J.P. Morgan Healthcare Conference with a months-long story idea ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...